Alpha2-Muscarnic Codrug Linkers for Dual Ocular Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and presbyopia using alpha2 adrenergic and muscarinic agonists are limited by separate dosing requirements and potential washout concerns, and the mechanisms of action for muscarinic agonists in treating presbyopia are not fully understood.
Innovation Solution
A co-drug is developed that covalently links an alpha2 adrenergic agonist and a muscarinic agonist via ester or amide bonds, allowing for selective in vivo cleavage to release both drugs, providing synergistic effects on target diseases like glaucoma and presbyopia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate administration of alpha2 adrenergic agonists and muscarinic agonists is used, then each drug can be delivered independently, but the therapeutic efficacy and synergistic effects are limited
Solution Approach 1:
The patent combines two separate drugs (alpha2 adrenergic agonist and muscarinic agonist) into a single codrug molecule through covalent bonding. This merging allows both drugs to be administered simultaneously in a single formulation, enabling synergistic effects while improving therapeutic efficacy for glaucoma and presbyopia treatment.
Solution Approach 2:
The codrug is designed with a cleavable linker that can be selectively broken in vivo to release the two individual drug molecules. This segmentation allows the combined drug to function as a single entity during delivery, then separate into its active components at the target site, resolving the contradiction between unified delivery and individual drug action.
2Adaptability or versatility
If alpha2 adrenergic agonists are used alone, then the treatment mechanism is limited to alpha2 receptor activation, but combining with muscarinic agonists requires complex formulation and administration
Solution Approach 1:
By merging the alpha2 adrenergic agonist and muscarinic agonist into a single codrug molecule, the invention provides dual mechanism of action (both alpha2 and muscarinic receptor activation) while simplifying administration to a single dose, eliminating the need for complex combination formulations.
Solution Approach 2:
The codrug structure enables a single molecular entity to perform multiple functions: it acts as both an alpha2 adrenergic agonist and a muscarinic agonist, providing versatile therapeutic effects for multiple ocular conditions including glaucoma and presbyopia through different receptor mechanisms.
3Quantity of substance
If codrug with covalent bonds is used, then simultaneous delivery of both drugs is achieved, but the chemical stability and controlled release require precise bond selection
Solution Approach 1:
The patent introduces a cleavable linker as an intermediary component between the two drug moieties. This linker serves as a mediator that maintains the stability of the codrug structure during delivery, while being designed to undergo selective hydrolysis or enzymatic cleavage at the target site, enabling controlled release of both drugs.
Solution Approach 2:
The invention utilizes changes in chemical environment (pH, enzymatic activity) between the administration site and target tissue to trigger bond cleavage. The covalent bonds are designed with specific chemical parameters that remain stable under circulation conditions but change under physiological conditions at the target site, enabling controlled drug release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The co-drug offers simultaneous dosing and improved efficacy for treating glaucoma and presbyopia by enhancing pupil constriction and fluid outflow, addressing the limitations of separate drug administration and unclear mechanisms of action.
Implementation Method 1
the link comprises an ester bond, an amide bond, a carbamate bond, or a combination thereof
Data Source
AI summary
A co-drug or a pharmaceutical salt thereof includes a muscarinic agonist moiety and an alpha2 adrenergic agonist moiety. The muscarinic agonist moiety and the alpha2 adrenergic agonist moiety are connected covalently via a linker, and the link includes an ester bond, an amide bond, a carbamate bond, or a combination thereof.